Joseph A O'Donoghue

First-in-Human Human Epidermal Growth Factor Receptor 2–Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer

Gary A Ulaner, Pat B Zanzonico, D. Lake, 2017, The Journal of Nuclear Medicine.

Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor mo

C Clifton Ling, Pat Zanzonico, Andrei Pugachev, 2005, International journal of radiation oncology, biology, physics.

18F-Fluromisonidazole PET Imaging as a Biomarker for the Response to 5,6-Dimethylxanthenone-4-Acetic Acid in Colorectal Xenograft Tumors

C Clifton Ling, Pat Zanzonico, C. Ling, 2011, The Journal of Nuclear Medicine.

CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.

Gary A Ulaner, Serge K. Lyashchenko, Lukas M Carter, 2020, Radiology.

Monitoring early response to chemoradiotherapy with 18F-FMISO dynamic PET in head and neck cancer

Bradley J Beattie, Nadeem Riaz, Heiko Schöder, 2017, European Journal of Nuclear Medicine and Molecular Imaging.

Rationales, evidence, and design considerations for fractionated radioimmunotherapy

George Sgouros, Donald J Buchsbaum, John L Humm, 2002, Cancer.